Home > Boards > US Listed > Biotechs > Cytori Therapeutics, Inc. (CYTX)

NEWS -- Cytori to Webcast Fourth Quarter and

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 64
Posts 10,116
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2019 6:09:06 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 6:41:20 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/7/2019 6:25:28 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/3/2019 4:43:30 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/27/2019 11:18:48 AM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 9/24/2019 4:07:28 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/24/2019 6:00:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2019 5:21:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2019 6:35:17 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 9/16/2019 4:08:45 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 9/16/2019 4:04:06 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 9/10/2019 7:24:06 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 6:22:47 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/26/2019 4:08:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2019 8:01:33 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/15/2019 5:32:08 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/14/2019 5:10:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 4:33:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 8:00:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/2/2019 4:05:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 8:01:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/23/2019 8:01:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/16/2019 4:51:16 PM
Cytori Will Become Plus Therapeutics, Inc. GlobeNewswire Inc. - 7/16/2019 4:15:00 PM
Cytori to Present Corporate Update & New Strategic Direction GlobeNewswire Inc. - 7/11/2019 8:00:00 PM
Paulness   Friday, 03/29/19 01:59:37 PM
Re: None
Post # of 2713 
NEWS -- Cytori to Webcast Fourth Quarter and 2018 Financial Results on April 1

Date : 03/29/2019 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Cytori Therapeutics (MM) (CYTX)

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year-end financial results and business update on Monday, April 1, 2019 at 8:30 AM Eastern Time.

The dial-in information is as follows:

Dial-In Number: +1.877.402.3914
Conference ID: 9699923

Prior to the webcast at approximately 8:15 AM Eastern Time on April 1, Cytori will issue its fourth quarter earnings release which will review Cytori’s third quarter and 2018 annual performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.

About Cytori Therapeutics, Inc.

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively. Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit www.cytori.com.

Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
mailto://ir@cytori.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist